KLK3 and prostate cancer: The SEER database had 9,114 prostate cancer patients with a GS of 8–10 and a pre-treatment PSA level of ≤ 10 ng/dL, among which 4,175 (45.8%) received RP, 4,114 (45.1%) received EBRT, and 825 (9.1%) received EBRT + BT with a median follow-up duration of 47 months (interquartile range [IQR], 34–60), 47 months (IQR, 34–60) for RP, 47 months (IQR, 33–60) for EBRT, and 51 months (IQR, 37–62) for EBRT + BT.